Cipla profit misses estimates as US sales stay muted
Cipla's second-quarter net profit fell to 8.78 billion rupees, below analyst expectations, as muted US sales of generic Revlimid weighed on results.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
India's Cipla, the country's third-largest drugmaker by revenue, reported second-quarter profit below analyst forecasts on Tuesday. According to Reuters, weak sales of generic Revlimid and fierce competition in the US business dragged on the results.
The company's consolidated net profit for the quarter ended September 30 came to 8.78 billion rupees ($92.2 million), down from 13.51 billion rupees a year earlier. Analysts had expected 9.42 billion rupees on average, according to data compiled by LSEG.
why it matters
The US market remains central to Indian drugmakers' earnings, so weakness there quickly shows up in their profits. Investors will watch whether Cipla can rebuild US sales in the coming quarters.
market impact
Cipla shares: profit below forecasts and weak US business put pressure on the stock
- Cipla shares pressure down — profit below expectations and weak US sales worsen the company's outlook
tags
instruments
sources
- India's Cipla misses second-quarter profit view on muted US sales — Reuters, 27 October 2026 at 07:55 UTC
- Cipla misses second-quarter profit view on muted US sales — Moody's, 27 October 2026 at 10:24 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗